Join the Ozempic group to help and get support from people like you.
Ozempic News (Page 4)
GLP-1 Drug Use For Weight Loss Has Soared, Costing Billions
TUESDAY, April 1, 2025 – The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent years, a new study says. The number of people...
More Type 1 Diabetics Are Obese, Taking GLP-1 Drugs
MONDAY, March 31, 2025 – Use of cutting-edge weight-loss drugs like Ozempic and Zepbound has increased dramatically among people with type 1 diabetes, raising safety concerns among experts, a new...
Novo Nordisk To Pay $2 Billion for New Weight Loss Drug
TUESDAY, March 25, 2025 – Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity and diabetes drug, the company announced March...
Tirzepatide, Semaglutide Not Cost-Effective at Current Prices
WEDNESDAY, March 19, 2025 – Tirzepatide and semaglutide offer long-term health benefits but are not cost-effective, according to a study published online March 14 in JAMA Health Forum. Jennifer H....
GLP-1 RA Use Tied to Better Kidney Transplant Outcomes in Patients With Diabetes
TUESDAY, March 18, 2025 – Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with better graft and patient survival among kidney transplant recipients with diabetes, according to...
No Weight Loss Benefit Seen for Neoadjuvant Semaglutide Before Weight Loss Surgery
WEDNESDAY, March 12, 2025 – Neoadjuvant semaglutide before metabolic and bariatric surgery (MBS) is not beneficial in terms of weight loss, according to a research letter published online March 5 in...
AAOS: Stopping GLP-1 RAs 14 Days Before Surgery Can Minimize Complications
TUESDAY, March 11, 2025 – Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize risks for complications, according to a study...
Risk for Specific Hematologic Cancers Down With GLP-1 Receptor Agonist Use in T2DM
MONDAY, March 10, 2025 – For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers...
No Link Seen Between Preop GLP-1 Receptor Agonist Use and Postop Aspiration Pneumonia
THURSDAY, March 6, 2025 – Preoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is not associated with short-term postoperative aspiration pneumonia, according to a study published...
GLP-1 Drugs Improve Outlook For Kidney Transplants
THURSDAY, March 6, 2025 – GLP-1 drugs like Ozempic can help kidney transplant patients avoid organ failure and live longer, a new study suggests. The drugs help manage patients’ type 2 diabetes and p...
Obesity On The Rise Worldwide, Report Says
TUESDAY, March 4, 2025 – More than half of adults and a third of children and teens worldwide will be overweight or obese by 2050, a comprehensive global analysis has concluded. Overweight and...
GLP-1 Receptor Agonist Use Not Linked to Increased Suicide Risk
MONDAY, March 3, 2025 – Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with dipeptidyl peptidase-4 (DPP-4) inhibitors or...
Semaglutide May Reduce Craving in Alcohol Use Disorder
FRIDAY, Feb. 28, 2025 – Low-dose semaglutide seems to reduce craving and certain drinking outcomes in alcohol use disorder (AUD), according to a study published online Feb. 12 in JAMA Psychiatry....
No Suicide Risk Associated With GLP-1 Drugs
FRIDAY, Feb. 28, 2025 – GLP-1 drugs like Ozempic/Wegovy don’t increase a person’s risk of suicidal actions or thoughts, a new study has concluded. Earlier research had potentially linked these drugs ...
Depression Risk Lower With GLP-1 Receptor Agonists Versus DPP-4 Inhibitors in Seniors
MONDAY, Feb. 24, 2025 – For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a modestly lower risk for depression compared...
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Chronic Kidney Disease, Cardiovascular Risk Reduction, Diabetes, Type 2